Abstract
This Practice Point commentary discusses the DART-AD trial, a prospective study investigating neuroleptic discontinuation. Patients with dementia of the Alzheimer type who were in residential care and taking neuroleptics for 3 months or longer, were randomized to receive one of two 12-month interventions: continuation or discontinuation of neuroleptic treatment. The primary aim was to determine whether neuroleptic discontinuation improves cognitive outcomes. After 6 months, neuroleptic discontinuation was not detrimental to cognition or function in patients with Alzheimer's disease, except for those who had Neuropsychiatric Inventory scores ≥15 at enrollment (these patients had even higher Neuropsychiatric Inventory scores at 12 months). This commentary highlights methodological issues pertinent to the translation of these results and also considers implications for everyday practice. From a practice perspective, it would seem that judicious prescribing and timely discontinuation might optimize the risk–benefit balance of neuroleptics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schneider LS et al. (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934–1943
Wang PS et al. (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353: 2335–2341
Bridges-Parlet S et al. (1997) Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. J Geriatr Psychiatry Neurol 10: 119–126
Cohen-Mansfield J et al. (1999) Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 159: 1733–1740
Ballard CG et al. (2004) A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 65: 114–119
Ballard C et al. (2008) A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 5: e76
Lakey SL et al. (2006) Psychotropic use in community residential care facilities: a prospective cohort study. Am J Geriatr Pharmacother 4: 227–235
Aalten P et al. (2005) The course of neuropsychiatric symptoms in dementia: part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry 20: 523–530
Acknowledgements
The work of the author is supported by a grant from the National Institute of Mental Health and the National Institute on Aging RO1MH060626.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Onyike, C. Neuroleptic discontinuation during dementia care: a recent trial and its implications for practice. Nat Rev Neurol 4, 528–529 (2008). https://doi.org/10.1038/ncpneuro0884
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0884
